Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 4/20 | 0.41 |
| ▸ | HTR7 | P34969 | 14/20 | 0.41 |
| ▸ | HTR2A | P28223 | 13/20 | 0.41 |
| ▸ | HTR6 | P50406 | 13/20 | 0.41 |
| ▸ | DRD2 | P14416 | 12/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2963869 | 0.89 | EPAS1 (0.45) | EPAS1HTR7HTR2AHTR6DRD2 | |
| SCHEMBL2962304 | 0.85 | EPAS1 (0.39) | EPAS1HTR7HTR2AHTR6DRD2 | |
| SCHEMBL2968422 | 0.82 | EPAS1 (0.49) | EPAS1HTR7HTR2AHTR6DRD2 | |
| SCHEMBL6111296 | 0.80 | HTR2A (0.43) | EPAS1HTR7HTR2AHTR6DRD2 | |
| SCHEMBL2976560 | 0.80 | HTR7 (0.40) | EPAS1HTR7HTR2AHTR6DRD2 | |
| SCHEMBL2968754 | 0.79 | LMNA (0.42) | EPAS1HTR7HTR2AHTR6DRD2 | |
| SCHEMBL2966950 | 0.78 | FABP4 (0.42) | EPAS1HTR7HTR2AHTR6DRD2 | |
| SCHEMBL2967891 | 0.77 | EPAS1 (0.39) | EPAS1HTR7HTR2AHTR6DRD2 | |
| SCHEMBL2967232 | 0.77 | SMN1; SMN2 (0.49) | HTR7HTR2AHTR6DRD2 | |
| SCHEMBL13220567 | 0.76 | CA12 (0.55) | EPAS1HTR7HTR2AHTR6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | claimed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | HAVCR2, ZC3HAV1, MAVS | EPAS1 917/4885HTR7 3619/4885HTR2A 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.